Group 1 - The core viewpoint of the articles highlights the continuous emergence of innovative drug research and development results from domestic companies in China, with a significant shift in foreign companies' reliance on patented original drugs for profit [1][3] - During the "14th Five-Year Plan" period, China approved 210 innovative drugs and 269 innovative medical devices, both showing an accelerating growth trend [1] - China's biopharmaceutical market has become the second largest globally, with approximately 30% of the world's innovative drugs under development [1] Group 2 - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking 30 representative high-quality companies [2] - From September 24, 2024, to September 30, 2025, during the market rebound, the Sci-Tech Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovative Drug Index recorded gains of 117.04% and 109.62%, respectively [2] - The Sci-Tech Innovation Drug Index may help investors better share the elasticity of the Sci-Tech Innovation Board when market risk appetite increases [2]
20cm速递|国内企业创新药研发成果持续涌现，科创创新药ETF国泰（589720）回调超3%，资金逢低布局，近20日净流入近2亿元
Mei Ri Jing Ji Xin Wen·2025-11-17 06:37